Literature DB >> 22722900

Particulate systems for targeting of macrophages: basic and therapeutic concepts.

S M Moghimi1, L Parhamifar, D Ahmadvand, P P Wibroe, T L Andresen, Z S Farhangrazi, A C Hunter.   

Abstract

Particulate systems in the form of liposomes, polymeric micelles, polymeric nano- and microparticles, and many others offer a rational approach for selective delivery of therapeutic agents to the macrophage from different physiological portals of entry. Particulate targeting of macrophages and intracellular drug release processes can be optimized through modifications of the drug carrier physicochemical properties, which include hydrodynamic size, shape, composition and surface characteristics. Through such modifications together with understanding of macrophage cell biology, targeting may be aimed at a particular subset of macrophages. Advances in basic and therapeutic concepts of particulate targeting of macrophages and related nanotechnology approaches for immune cell modifications are discussed.
Copyright © 2012 S. Karger AG, Basel.

Mesh:

Substances:

Year:  2012        PMID: 22722900     DOI: 10.1159/000339153

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  19 in total

1.  Innate immune functions of macrophages in different tissue environments.

Authors:  Siamon Gordon
Journal:  J Innate Immun       Date:  2012-06-12       Impact factor: 7.349

Review 2.  Sinusoidal immunity: macrophages at the lymphohematopoietic interface.

Authors:  Siamon Gordon; Annette Plüddemann; Subhankar Mukhopadhyay
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-12-11       Impact factor: 10.005

3.  Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy.

Authors:  Seyed Moein Moghimi; Fatemeh Rahbarizadeh; Davoud Ahmadvand; Ladan Parhamifar
Journal:  Bioimpacts       Date:  2013-01-27

Review 4.  Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease.

Authors:  Katherine A Roach; Aleksandr B Stefaniak; Jenny R Roberts
Journal:  J Immunotoxicol       Date:  2019-12       Impact factor: 3.000

Review 5.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.

Authors:  Marina A Dobrovolskaia; Scott E McNeil
Journal:  J Control Release       Date:  2013-06-03       Impact factor: 9.776

6.  Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Authors:  Jeremy A Bartlett; Marcus Brewster; Paul Brown; Donna Cabral-Lilly; Celia N Cruz; Raymond David; W Mark Eickhoff; Sabine Haubenreisser; Abigail Jacobs; Frank Malinoski; Elaine Morefield; Ritu Nalubola; Robert K Prud'homme; Nakissa Sadrieh; Christie M Sayes; Hripsime Shahbazian; Nanda Subbarao; Lawrence Tamarkin; Katherine Tyner; Rajendra Uppoor; Margaret Whittaker-Caulk; William Zamboni
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

7.  Complement activation turnover on surfaces of nanoparticles.

Authors:  S M Moghimi; D Simberg
Journal:  Nano Today       Date:  2017-04-12       Impact factor: 20.722

8.  C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.

Authors:  Regina Tavano; Luca Gabrielli; Elisa Lubian; Chiara Fedeli; Silvia Visentin; Patrizia Polverino De Laureto; Giorgio Arrigoni; Alessandra Geffner-Smith; Fangfang Chen; Dmitri Simberg; Giulia Morgese; Edmondo M Benetti; Linping Wu; Seyed Moein Moghimi; Fabrizio Mancin; Emanuele Papini
Journal:  ACS Nano       Date:  2018-05-23       Impact factor: 15.881

Review 9.  Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.

Authors:  William T Phillips; Ande Bao; Andrew J Brenner; Beth A Goins
Journal:  Adv Drug Deliv Rev       Date:  2014-07-09       Impact factor: 15.470

10.  Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.

Authors:  Emiliano Cocco; Yang Deng; Erik M Shapiro; Ileana Bortolomai; Salvatore Lopez; Ken Lin; Stefania Bellone; Jiajia Cui; Gulden Menderes; Jonathan D Black; Carlton L Schwab; Elena Bonazzoli; Fan Yang; Federica Predolini; Luca Zammataro; Gary Altwerger; Christopher de Haydu; Mitchell Clark; Julio Alvarenga; Elena Ratner; Masoud Azodi; Dan-Arin Silasi; Peter E Schwartz; Babak Litkouhi; W Mark Saltzman; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2016-12-12       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.